Triple targeted therapy for advanced bowel cancer improves survival
Patients with metastatic colorectal cancer who have a BRAF mutation have improved survival after treatment with three targeted therapies instead of standard chemotherapy, results from a phase III trial have shown.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Bowel Cancer | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Drugs & Pharmacology